Age is a factor when looking at diabetes management, Sanofi survey finds

15 October 2014

The US subsidiary of French pharma major Sanofi (Euronext: SAN) has announced the findings of a new survey that reveals striking differences in opinions among various age groups about diabetes and available treatment options.

The survey found that the generation known as ‘millennials’ (those aged 18 to 34) shows a mix of fear and ability to handle managing their diabetes, which is being diagnosed at a rate of 1.7 million new cases every year. However, millennials rate themselves having better knowledge of diabetes than Americans aged 35 and older, with 72% of millennials indicating they are well versed about the condition versus the 64% of non-millennials who expressed some knowledge about diabetes. Despite this self-reported understanding, millennials are less likely than older populations to think that diabetes is a serious health condition; overall, 74% of millennials think it is serious compared with 84% of the older survey respondents. In addition, more than two-fifths of millennials (43%) report they are scared of pricking their finger to monitor blood sugar levels, compared with 28% of older respondents.

Attitudes towards insulin

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical